In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report), with a price target of $20.00. The company's shares closed last Friday at $14.55, close to its 52-week high of $14.82. According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.8% and a 36.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and Dermata Therapeutics. Sensus Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $16.88, representing a 34.2% upside.
https://www.tipranks.com/news/blurbs/sensus-healthcare-srts-receives-a-buy-from-maxim-group-2?utm_source=advfn.com&utm_medium=referral
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Sensus Healthcare Charts.
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Sensus Healthcare Charts.